SIDNEY WALLACE
Medical Practice in Houston, TX

5728843, Mar 17, 1998

Apr 4, 1996

8/624574

Sidney Wallace - Houston TX
David J. Yang - Sugarland TX
Abdallah Cherif - Houston TX

Wallace Technologies - Houston TX

C07D23328, C07D23391, C07D23354, C07D51300, A61K 31415

5483275

The present invention involves a rapid synthesis of. sup. 18 F-FMISO and analogs thereof. New precursors such as 1-(2'-nitro-1'-imidazolyl)-2-0-acetyl-3-0-tosylpropanol, glycerol-1,3-ditosylate-2-0-acetylate, 1-(2'-nitro-1'-imidazolyl)-2,3-0-diacetylate, are also important aspects of the invention. A further aspect of the invention is the development of a hydrophilic PET ligand to image tumor hypoxia. Erythrotosyl analogue of 2-nitroimidazone (Ts-ETNIM) was prepared from a mixture of 2-nitromidazole, ditosylthreitol and cesium carbonate at 60. degree. C. for 1 hr. Ts-ETNIM was isolated at 70% yield. �. sup. 18 F!fluoroerythronitroimidazole (FETNIM) when prepared from Ts-ETNIM and K. sup. 18 F/kryptofix. RTM. The yield for �. sup.

6730699, May 4, 2004

Nov 20, 2002

10/300031

Chun Li - Missouri City TX
Sidney Wallace - Houston TX
Dong-Fang Yu - Houston TX
David Yang - Sugar Land TX

PG-TXL Company, L.P. - Houston TX

A61K 31335

514449, 514510, 514511, 424486

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

5643317, Jul 1, 1997

May 27, 1994

8/244580

Dusan Pavcnik - Nova Gorica, SI
Sidney Wallace - Houston TX
Kenneth C. Wright - Houston TX

William Cook Europe S.A. - Bjaeverskov

A61B 1708

606213

A closure prosthesis and transcatheter delivery system includes a closure prosthesis for sealing across all opening of a fluid passageway within a living body. The closure prosthesis is a flexible disk including a flexible ring and diaphragm having a plurality of hollow flexible wire segments attached thereto. Delivery of the closure prosthesis is accomplished using a hollow sheath and a pusher catheter slidable within the sheath, wherein filaments are looped through the wire segments to releasably connect the disk to the pusher catheter. The disk is resiliently compressed within the sheath and, upon release therefrom, the disk resiliently expands into a larger, unrestrained shape. Tension applied to the filaments resiliently bends the wire segments so that they may be drawn through the opening of the defect. Upon releasing the filaments from the disk, the wire segments resiliently expand to trap the disk in place to seal across the opening.

2003021, Nov 20, 2003

Mar 20, 2003

10/391152

Andras Konya - Houston TX, US
Sidney Wallace - Houston TX, US
Kenneth Wright - Houston TX, US

Board of Regents, University of Texas System

A61M029/00

606/195000

A coil-type vasoocclusion device () for establishing an embolus or vascular occlusion in a human or veterinary patient is adapted for introduction into the patient via a catheter (). The device () first includes a coil () having proximal and distal coil ends () and a coil lumen (). The device () also includes a core () disposed in at least part of the coil lumen (), the core having proximal and distal core ends (). Only one core end (or ) is directly affixed to a respective end (or ) of the coil (); the other core end (or ) is not directly connected to either end (or ) of the coil (). The core () is preferably nitinol in a superelastic state, being in other than its stress induced, martensitic condition. The device () can include a thrombogenic material () connected to or carried by the coil (). The coil () is preferably adapted to achieve a suitable secondary shape () when deployed from the catheter (). A medical device () combining the catheter (), a pusher (), a coupling () and the vasoocclusion device () is also disclosed. The vasoocclusion device () is easily repositioned in the vascular system, thereby ensuring proper deployment, and also enjoys a dislodging force about twice as great as comparable coil-type devices lacking the core (), substantially or completely preventing migration of the device () after its deployment.

5397351, Mar 14, 1995

May 13, 1991

7/699195

Dusan Pavcnik - Nova Gorica, Slovenija, 65000, YU
Sidney Wallace - Houston TX
Kenneth C. Wright - Houston TX

A61F 202, A61F 224

623 11

A prosthetic valve comprises a poppet, a seat and a restraining element. The poppet, seat and restraining element include an insertion form for percutaneously inserting into a fluid passageway within a living body and an operational form for operating within the fluid passageway. The valve is self-expanding so that upon insertion the valve automatically assumes the operational form. In the operational form the poppet is movably restrained between the valve seat and restraining element. The poppet seals against the valve seat to prevent fluid flow through the valve and unseats from the valve seat to permit fluid flow through the valve.

2003011, Jun 19, 2003

Sep 12, 2002

10/243080

Chun Li - Missouri City TX, US
Sidney Wallace - Houston TX, US
Dong-Fang Yu - Houston TX, US
David Yang - Sugar Land TX, US

PG-TXL Company, L.P.

A61K038/16, A61K038/14, C07K009/00, C07K014/00

514/008000, 514/012000, 530/322000, 530/324000

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

2008015, Jun 26, 2008

Oct 29, 2007

11/927392

Chun Li - Missouri City TX, US
Sidney Wallace - Houston TX, US
Dong-Fang Yu - Houston TX, US
David Young - Sugar Land TX, US

A61K 31/4375, A61P 35/04

514283

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

5886190, Mar 23, 1999

Nov 26, 1997

8/979051

Sidney Wallace - Houston TX
David J. Yang - Sugarland TX
Abdallah Cherif - Houston TX

C07D23391

5483325

The present invention involves a rapid synthesis of. sup. 18 F-FMISO and analogs thereof. New precursors such as 1-(2'-nitro-1'-imidazolyl)-2-0-acetyl-3-0-tosylpropanol, glycerol-1,3-ditosylate-2-0-acetylate, 1-(2'-nitro-1'-imidazolyl)-2,3-0-diacetyl-4-0-tosylbutanol and threitol 1,4-di-tosylate-2,3-0-diacetylate, are also important aspects of the invention. A further aspect of the invention is the development of a hydrophilic PET ligand to image tumor hypoxia. Erythrotosyl analogue of 2-nitroimidazone (Ts-ETNIM) was prepared from a mixture of 2-nitromidazole, ditosylthreitol and cesium carbonate at 60. degree. C. for 1 hr. Ts-ETNIM was isolated at 70% yield. �. sup. 18 F!fluoroerythronitroimidazole (FETNIM) was then prepared from Ts-ETNIM and K. sup. 18 F/kryptofix. RTM. The yield for �. sup.

5350398, Sep 27, 1994

May 28, 1993

8/068594

Dusan Pavcnik - Slovenija, 65000, YU
Sidney Wallace - Houston TX
Kenneth C. Wright - Houston TX

A61M 2900

606200

A flexible vena cava filter comprises a flexible stent having a plurality of flexible wire segments attached across the ends of the stent. The filter is resiliently compressible for percutaneous insertion into a fluid passageway and expands against the passageway upon placement therein. The filter includes different levels of filtration.

2003014, Aug 7, 2003

Dec 5, 2002

10/310331

Chun Li - Missouri City TX, US
Sidney Wallace - Houston TX, US
Dong-Fang Yu - Houston TX, US
David Yang - Sugar Land TX, US

PG-TXL Company, L.P.

A61K051/00, A61K031/7048, A61K031/337, A61K031/4745, A61K031/427, A61K031/555

424/001110, 514/027000, 514/449000, 514/283000, 514/365000, 514/184000

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.